Nealkogol'naya zhirovaya bolezn' pechenipri ozhirenii

Cover Page

Abstract


Non-alcoholic fatty liver disease (NAFLD) is a common chronic disease, uniting clinical and pathological changes in a liver:
steatosis, non-alcoholic steatohepatitis, fibrosis and cirrhosis. NAFLD is associated with obesity especially of abdominal type and metabolic
syndrome, that raises cardiometabolic risk and effects morbidity, prognosis of the disease and life expectancy of patients. This article
describes the basic mechanisms of development of NAFLD, classification, prognosis of the disease, diagnosis and treatment.

  1. Буеверов А.О., Богомолов П.О., Маевская М.В. Патогенетическое лечение неалкогольного стеатогепатита: обоснование, эффективность, безопасность // Терапевтический архив. - 2007. - № 79(8). - С. 1-4.
  2. Бутрова С.А., Елисеева А.Ю., Ильин А.В. Эффективность метформина и больных с метаболическим синдромом и неалкогольной жировой болезнью печени // Ожирение и метаболизм. - 2008. - № 2(15). - С. 17-21.
  3. Ивашкин В.Т., Драпкина О.М., Буеверова Е.Л. Статины и неалкогольная жировая болезнь печени: безопасность применения // Российские Медицинские Вести. - 2010. - № XV(1). - С. 17-26.
  4. Ивашкин В.Т., Драпкина О.М., Шульпекова Ю.О. Диагностика и лечение неалкогольной жировой болезни печени / Методические рекомендации. М.: ООО «Издательский дом «М-Вести», 2009.
  5. Никитин И.Г. Скрининговая программа по выявлению распространенности неалкогольной жировой болезни печени и определению факторов риска развития заболевания // Российские Медицинские Вести. - 2010. - № XV(1). - С. 41-6.
  6. Павлов Ч.С., Ивашкин В.Т. Биопсия печени: методология и практика сегодня // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2006. - № XVI(4). - С. 65-78.
  7. Adams L., Angulo P. Treatment of non-alcoholic fatty liver disease // Postgraduate medical Journal. - 2006. - № 82. - Р. 315-22.
  8. Alkhouri N., Dixon L., Feldstein A. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal // Expert review of gastroenterology & hepatology. - 2009. - № 3(4). - Р. 445-51.
  9. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury // J Clin Invest. - 2004. - № 114. - Р. 147-52.
  10. Browning J., Szczepaniak L., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity // Hepatology. - 2004. - № 40. - Р. 1387-95.
  11. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N. A randomized controlled trial of metformin versus vitamin E or or prescriptive diet in nonalcoholic fatty liver disease // Am J Gastroenterol. - 2005. - № 100. - Р. 1082-90.
  12. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., Ponti V., Pagano G., Ferrannini E., Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms // Diabetogia. - 2005. - № 48. - Р. 634-42.
  13. Chavez-Tapia N., Barrientos-Gutierrez T., Tellez-Avila F., Sanchez-Avila F., Montano-Reyes M., Uribe M. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review // World J Gastroenterol. - 2006. - № 12(48). - Р. 7826-31.
  14. Charles M., Morange P., Eschwege E. Effect of weight change and metformin on fibrinolisis and the von Willebrand factor in obese nondiabetic subjects // Diabetes care. - 1998. - № 21. - Р. 1967-72.
  15. Cnop M., Havel P., Utzschneider K. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasms lipoproteins: evidence for independent roles of age and sex // Diabetologia. - 2003. - № 46. - Р. 459-69.
  16. Dongiovanni P., Valenti L., R. Rametta., Daly A. K. et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease // Gut. - 2010. - № 59. - Р. 267-73.
  17. Ekstedt M., Franzen L., Mathiesen U. Statins in non-alcoholic fatty liver diseases and chronically elevated liver enzymes: a histopathological follow-up study // J hepatol. - 2007. - № 47(1). - Р. 135-41.
  18. Fassio E., Alvarez E., Dominguez N. Natural history of non-alcoholic steatohepatitis: a longitudinal study of liver biopsies // Hepatology. - 2004. - № 40. - Р. 820-6.
  19. Feldstein A., Charatcharoenwitthaya P., Treeprasertsuk S., Benson J., Enders F., Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow- up study for up to 20 years // Gut. - 2009. - № 58(11). - Р. 1538-44.
  20. Feldstein A.E., Wieckowska A.Е., Lopez A.R., Liu Y.C., Zein N.N., McCullough A.J. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study steatohepatitis // Hepatology. - 2004. - № 39(1). - Р. 188-96.
  21. Festi D., Colecchia A., Sacco T., Bondi M., Roda E., Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance // Obes Rev. - 2004. - № 5(1). - Р. 27-42.
  22. Ghany M., Premkumar A., Park Y., Liang T., Yanovski J., Kleiner D., Hoofnagle J. A pilot study of pioglitazone treatment for hepatitis // Hepatology. - 2009. - № 50(4). - Р. 564-8.
  23. Harrison S.A., Fecht W., Brunt E.M., Neuschwander-Tetri B.A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial // Hepatology. - 2009. - № 49(1). - Р. 80-6.
  24. Hasegawa Т., Yoneda M., Nakamura K., Makino I., Terano A. Plasma trans¬forming growth factor-betal level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study // Aliment. Pharmacol. Ther. - 2001. - № 15 (10). - Р. 1667-72.
  25. Houmard J.A., Tanner C.J., Slentz C.A. Effect of the volume and intensity of exercise training on insulin sensitivity // J Appl Physiol. - 2004. - № 96. - Р. 101-6.
  26. Hui J., Hodge A., Farrell G. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? // Hepatology. - 2004. - № 40. - Р. 46-54.
  27. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., Sanyal A.J. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease // Hepatology. - 2005 Jun. - № 41(6). - Р. 1313-21.
  28. Krempf M., Laville M., Basdevant A., et al. Effect of orlistat on NCEP ATP-IIIdefined metabolic syndrome in obese or overweight patients: meta-analysis from 20 randomised double-blind studies worldwide // Obese Rev. - 2005. - № 6(1). - Р. 166.
  29. Lazo M., Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective // Semin Liver Dis. - 2008. - № 28(4). - Р. 339-50.
  30. Marchesini G., Brizi M., Morselli-Labate A., Bianchi G., Bugianesi E., McCullough A., Forlani G., Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance // Am. J. Med. - 1999. - № 107 (5). - Р. 450-5.
  31. Marchesini G., Bianchi G., Tomassetti S., Zoli M., Melchionda N. Metformin in non-alcoholic steatohepatitis // The Lancet. - 2001. - № ). - Р. 893 - 4.
  32. Mazhar S., Shiehmorteza M., Sirlin C. Noninvasive assessment of hepatic steatosis // Clin Gastroenterol Hepatol. - 2009. - № 7(2). - Р. 135-40.
  33. Mehta R., Thomas E., Bell J., Johnston D., Taylor S. Non-invasive means of measuring hepatic fat content // World J Gastroenterol. - 2008. - № 14(22). - Р. 3476-83.
  34. Milner K., Van der Poorten D., Xu A., Bugianesi E., Kench J., Lam K., Chisholm D., George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease // Hepatology. - 2009. - № 49(6). - Р. 1926-34.
  35. Mofrad P., Contos M., Haque M. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values // Hepatology. - 2003. - № 37. - Р. 1286-92.
  36. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update // Obesity Reviews. - 2010. - № 11(6). - Р. 430-45.
  37. Nair S., Diehl A., Wiseman M. Metformin in the triement of non- alcoholic steatohepatitis: a pilot open label trial // Aliment Pharmacol Ther. - 2004. - № 20. - Р. 23-8.
  38. Sabuncu T., Nazligui Y., Karaoglanoglu M. et al. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis // Rom. J. Gastroentarol. - 2003. - № 12. - Р. 189-92.
  39. Schwenzer N., Springer F., Schraml C., Stefan N., Machann J., Schick F. Noninvasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance // J Hepatol. - 2009. - № 51(3). - Р. 433-45.
  40. Stefan N., Kantartzis K., Häring H. Causes and Metabolic Consequences of Fatty Liver // Endocrine Reviews. - 2008. - № 29(7). - Р. 939-60.
  41. Targher G., Bertolini L., Scala L., Zoppini G., Zenari L., Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue // Diabet Med. - 2005. - № 22(10). - Р. 1354-8.
  42. Tiikkainen M., Hakkinen A., Korsheninnikova E. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes // Diabetes. - 2004. - № 53. - Р. 2169-76.
  43. Tilg H., Diehl A. Cytokines in alcoholic and nonalcoholic steatohepatitis // N Engl J Med. - 2000. - № 343(20). - Р. 1467-76.
  44. Tilg H., Diehl A., Li Z., Lin H., Yang S. Cytokines and the pathogenesis of nonalcoholic steatohepatitis // Gut. - 2005. - № 54. - Р. 303-6.
  45. Tobari M., Hashimoto E. Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography // Intern Med. - 2009. - № 48(10). - Р. 739-46.
  46. Toplak H., Ziegler O., Keller U., et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance // Diabetes Obes Metab. - 2005. - № 7(6). - Р. 699-708.
  47. Torer N., Ozenirler S., Yucel A., Bukan N., Erdem O. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis // Scandiavian Journal of Gastroenterology. - 2007. - № 42 (9). - Р. 1095-101.
  48. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients // Diabetes Care. - 2004. - № 27(1). - Р. 155-61.
  49. Tushuizen M.E., Bunck M.C., Pouwels P.J., et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis // Liver Int. - 2006. - № 26. - Р. 1015-7.
  50. Utzschneider K.M., Kahn S.E. The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease // The Journal of Clinical Endocrinology & Metabolism. - 2006. - № 91(12). - Р. 4753-61.
  51. Uygun A., Kadayifci A., Isik A.T., Ozgurtas T., Deveci S., Tuzun A., Yesilova Z., Gulsen M., Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis // Aliment Pharmacol Ther. - 2004. - № 19(5). - Р. 537-44.
  52. Webb M., Yeshua H., Zelber-Sagi S., Santo E., Brazowski E., Halpern Z., Oren R. Diagnostic Value of a Computerized Hepatorenal Index for Sonographic Quantification of Liver Steatosis // AJR. - 2009. - № 192. - Р. 909-14.
  53. Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL-Primary Health Care Trial // Diabetes Obes Metab. - 2005. - № 7(1). - Р. 21-7.
  54. Zelber-Sagi S., Kessler A., Brazowsky E., et al. A double-blind randomized placebocontrolled trial of orlistat for the treatment of nonalcoholic fatty liver disease // Clin Gastroenterol Hepatol. - 2006. - № 4. - Р. 639-44.
  55. Zheng L., Lv G., Sheng J., Yang Y. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-α expression, a novel mechanism for the pathogenesis of NAFLD // J. Gastroenterol. Hepatol. - 2010. - № 25(1). - Р. 156-63.

Views

Abstract - 804

PDF (Russian) - 1459

Cited-By


Dimensions


Copyright (c) 2011 Komshilova K.A., Troshina E.A., Butrova S.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies